Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03679156

Enrollment

Registered

2018-09-20

Start date

2016-05-30

Completion date

2017-04-15

Last updated

2018-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Age-related Macular Degeneration

Brief summary

Purpose: To assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term follow-up and to evaluate morphological markers potentially influencing prognosis. Methods: 18 patients (18 eyes) with neovascular AMD were recruited subsequent to completion the Avastin Versus Lucentis in Age Related Macular Degeneration (MANTA) study following a mean period of 84 months (range: 69-93 months). After receiving a loading dose of 3 intravitreal anti-VEGF injections subsequent to baseline of the MANTA study, patients were treated as-needed \[pro re nata (PRN)\]. Functional and morphological changes were assessed using spectral domain optical coherence tomography (SD-OCT).

Interventions

DEVICEOCT

Patients were recruited, visual acuity and optical coherence tomography Pictures were taken

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

66 Years to 98 Years

Healthy volunteers

Inclusion criteria

* Inclusion and

Exclusion criteria

corresponded to the criteria of the MANTA study

Design outcomes

Primary

Measure	Time frame	Description
visual acuity	93 months	visual acuity testing was performed

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026